Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00701
|
|||||
| Drug Name |
Fosinopril
|
|||||
| Synonyms |
fosinopril; (2S,4S)-4-cyclohexyl-1-(2-{[2-methyl-1-(propanoyloxy)propoxy](4-phenylbutyl)phosphoryl}acetyl)pyrrolidine-2-carboxylic acid; 474519-28-3; C30H46NO7P; (2S,4S)-4-cyclohexyl-1-[2-[(2-methyl-1-propanoyloxypropoxy)-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid; SR-05000001490; SCHEMBL15626; AC1L1K09; CHEMBL3306578; DTXSID1023079; HMS3715N21; HMS2089P08
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | High blood pressure [ICD11: BA00] | Approved | [1] | |||
| Therapeutic Class |
Antihypertensive Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C30H46NO7P
|
|||||
| Canonical SMILES |
CCC(=O)OC(C(C)C)OP(=O)(CCCCC1=CC=CC=C1)CC(=O)N2CC(CC2C(=O)O)C3CCCCC3
|
|||||
| InChI |
InChI=1S/C30H46NO7P/c1-4-28(33)37-30(22(2)3)38-39(36,18-12-11-15-23-13-7-5-8-14-23)21-27(32)31-20-25(19-26(31)29(34)35)24-16-9-6-10-17-24/h5,7-8,13-14,22,24-26,30H,4,6,9-12,15-21H2,1-3H3,(H,34,35)/t25-,26+,30?,39?/m1/s1
|
|||||
| InChIKey |
BIDNLKIUORFRQP-FKDWWROVSA-N
|
|||||
| CAS Number |
CAS 98048-97-6
|
|||||
| Pharmaceutical Properties | Molecular Weight | 563.7 | Topological Polar Surface Area | 110 | ||
| Heavy Atom Count | 39 | Rotatable Bond Count | 15 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 7 | |||
| XLogP |
6.2
|
|||||
| PubChem CID | ||||||
| PubChem SID | ||||||
| ChEBI ID |
CHEBI:5163
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | PEPT1 | Transporter Info | Peptide transporter 1 | Substrate | [2] | |
| PEPT2 | Transporter Info | Peptide transporter 2 | Substrate | [3] | ||
| References | ||||||
| 1 | Fosinopril was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. | |||||
| 3 | Mechanism of intestinal absorption and renal reabsorption of an orally active ace inhibitor: uptake and transport of fosinopril in cell cultures. Drug Metab Dispos. 2001 Oct;29(10):1307-15. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.